Single domain antibodies that bind to human CD20
AssigneeThe United States of America as represented by the Secretary of the Navy
InventorsJinny Lin Liu, Daniel Zabetakis, Ellen R. Goldman, George P. Anderson
Life of this patent
Estimating the term…
Abstract
Described herein is the development of recombinant single domain antibodies, also known as nanobodies, that may provide better therapeutic results or be useful for diagnostic applications of B-cell lymphomas, or in other applications where an antibody to CD20 may be useful.
Claims6
An isolated anti-CD20 single domain antibody comprising the amino acid sequence of SEQ ID NO:
- 2, SEQ ID NO:
- 5, or SEQ ID NO:
- 6.
An isolated anti-CD20 single domain antibody comprising the amino acid sequence of SEQ ID NO:
- 16.
A pharmaceutical composition comprising:
- an isolated anti-CD20 single domain antibody comprising the amino acid sequence of SEQ ID NO:
- 2, SEQ ID NO:
- 5, or SEQ ID NO:
- 6;
- and a pharmaceutically acceptable carrier.
A pharmaceutical composition comprising:
- an isolated anti-CD20 single domain antibody comprising the amino acid sequence of SEQ ID NO:
- 16;
- and a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.